Novavax announces Memorandum of Understanding to explore expansion of COVID-19 vaccine activities in South Korea

Novavax and SK bioscience reaffirm partnership during meeting with South Korean leaders

A vial and sryinge are seen in front of a displayed Novavax logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration

Subscribe to our Telegram channel to get a daily dose of business and lifestyle news from NHA – News Hub Asia!

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding memorandum of understanding (MoU) with the Ministry of Health and Welfare of Korea (MOHW) and SK bioscience, Co. Limited, a vaccine business subsidiary of SK Group, to explore further cooperation in the development and manufacturing of vaccines, including NVX-CoV2373, Novavax’ recombinant protein COVID-19 vaccine candidate.

“Our strategic partnership with SK bioscience demonstrates Novavax’ commitment to global access to our vaccine, including for the people of South Korea and around the world,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “We thank the Ministry of Health and Welfare for its support as we work together toward the shared goal of promoting and enhancing global public health.”

The MoU was signed during a ceremony today hosted by President Moon Jae-in and attended by SK bioscience Chief Executive Officer Jaeyong Ahn, and Novavax President and Chief Executive Officer Stanley C. Erck, as well as business and government leaders from South Korea and the United States. The MoU builds on an existing manufacturing and licensing collaboration that is intended to provide broad and equitable access to NVX-CoV2373 in the Republic of Korea and globally.

“SK bioscience is proud to support production of Novavax’ COVID-19 vaccine candidate in South Korea,” said Jaeyong Ahn, Chief Executive Officer, SK bioscience. “We are committed to doing our part in the fight against COVID-19, in partnership with Novavax and the Ministry of Health and Welfare.”

Novavax and SK bioscience agreed to potentially explore the development of new vaccine products, including COVID-19 variant vaccines, and/or an influenza-COVID-19 combination vaccine. They will continue to collaborate in manufacturing of the vaccines utilizing SK bioscience’s facility, with support from the Korean government.

SK bioscience initiated the rolling submission process for NVX-CoV2373 in collaboration with Novavax to South Korea’s Ministry of Food and Drug Safety in April of this year.

Novavax Logo

Logo – https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

SOURCE Novavax, Inc.